Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618072 · ClinicalTrials.gov registry record · Phase 2
EMPOWIR:Enhance the Metabolic Profile of Women With Insulin Resistance
A Phase 2 study, sponsored by New York Medical College.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00618072 is a Phase 2 study that has completed, run by New York Medical College. The registered enrollment target is 46 participants.
The verdict
NCT00618072, a Phase 2 study, has completed, sponsored by New York Medical College.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The goal of the study is to identify and treat women with midlife weight gain who have normal blood sugars, but increased insulin levels (hyperinsulinemia) following the performance of a glucose tolerance test. The study will evaluate effects of a unique carbohydrate modified diet alone and in combination with metformin(MF) and Avandamet® (MF plus rosiglitazone (RSG)) on insulin levels in a wide range of ethnically diverse women (aged 35-55) at three academic medical centers. The primary study hypothesis is that insulin sensitizing medications, in combination with alterations in carbohydrate intake, will reduce insulin levels and improve established risk factors for the metabolic syndrome. The alarming prevalence of obesity, diabetes, and related comorbidities and the paucity of easily adopted, cost-effective preventive strategies for high risk populations, suggest that pharmaco-therapies and dietary regimens targeted to reducing insulin resistance could have important clinical and public health implications.
Interventions
- DRUG metformin and rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00618072
The ClinicalTrials.gov registry entry for NCT00618072 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which metformin and rosiglitazone is the first listed.
NCT00618072 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00618072 about?
NCT00618072 is a clinical study titled "EMPOWIR:Enhance the Metabolic Profile of Women With Insulin Resistance". The goal of the study is to identify and treat women with midlife weight gain who have normal blood sugars, but increased insulin levels (hyperinsulinemia) following the performance of a glucose tolerance test. The study will evaluate effects of a unique carbohydrate modified diet alone and in combi...
What is the current status of trial NCT00618072?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2008-01. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00618072?
The interventions under investigation include: metformin and rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00618072?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.